Business UpdateAug 11, 2026, 08:46 AM
AIM ImmunoTech CEO Highlights Ampligen's Biodefense Potential
AI Summary
AIM ImmunoTech Inc. announced that its CEO, Thomas K. Equels, published an article on Breaking Defense titled "Biodefense is force protection: Ready today, prepared for tomorrow." The article discusses the importance of military force readiness and highlights the potential of the Company's drug, Ampligen (rintatolimod), as a broad-spectrum early-onset and/or prophylactic antiviral therapeutic. It specifically addresses Ampligen's potential for Ebola virus disease and COVID-19, citing preclinical data and advocating for proactive evaluation of such countermeasures.
Key Highlights
- CEO Thomas K. Equels authored an article on biodefense for Breaking Defense.
- Article discusses Ampligen's potential as a broad-spectrum antiviral therapeutic.
- Highlights Ampligen for Ebola virus disease and COVID-19/related viruses.
- Preclinical data showed 100% survival in a lethal mouse model for Ebola.
- Advocates for proactive government-supported evaluation of prophylactic antivirals.
- Mentions past preclinical studies on Ampligen for SARS-related coronaviruses.
- Emphasizes biodefense as critical for military force protection and readiness.
Price Impact
More from AIM